Schering-Plough 2Q Revenues: $3.2 billion (+13%) 2Q Earnings: $539 million (+108%) YTD Revenues: $6.2 billion (+15%) YTD Earnings: $1.1 billion (+75%) Comments: SP’s Remicade sales were up 28% to $394 million. Nasonex sales grew 22% to $295 million. Combined Vytorin/Zetia sales were $1.3 billion (shared with Merck). R&D expenses rose $160 million to $696 million, including a $60 million upfront payment for a licensing deal with Novacea....